Introduction
Hypertension is the major risk factor for cardiovascular deaths and stroke. It accounts for an estimated 57% of all strokes and 24% of all ischemic heart disease events in India. [1] Hypertension prevalence in India accounts for 33% of urban and 25% of rural population. [2] In spite of this awareness, treatment and adequate control of hypertension is far from complete. The first comprehensive guideline for detection, evaluation, and management of high blood pressure (BP) was published in 1977, under the sponsorship of the National Heart, Lung, and Blood Institute. [3] In subsequent years, a series of Joint National Committee (JNC) BP guidelines were published to assist the clinicians to improve prevention, awareness, treatment, and control of high BP. [4] To address the existing controversies and to account for the evidence from the new randomized controlled trials on hypertension, the American College of Cardiology (ACC)/American Heart Association (AHA) and the European Society of Cardiology/European Society of Hypertension (ESC/ESH) have come up with new guidelines for hypertension. [5, 6] The newer guidelines emphasized on the accuracy as well as out-of-office BP measurement, classification of BP, new approach to decision-making for treatment that incorporates underlying cardiovascular risk, lower targets for BP, and strategies to improve BP control during treatment with an emphasis on lifestyle approaches.
Classification
In a meta-analysis of 61 prospective studies, the risk of cardiovascular diseases (CVD) increased in a log-linear fashion from systolic blood pressure (SBP) levels <115 mmHg to >180 mmHg and from diastolic blood pressure (DBP) levels <75 mmHg to >105 mmHg. [7] In that analysis, 20 mmHg higher SBP and 10 mmHg higher DBP were each associated with a doubling in the risk of death from stroke, heart disease, or other vascular diseases. Although the relative risk of incident CVD associated with higher SBP and DBP is smaller at older ages, the corresponding high BP-related increase in absolute risk is larger in older persons (>65 years) given the higher absolute risk of CVD at an older age.
Although a continuous association exists between higher BP and increased CVD risk, it is useful to classify BP levels for clinical and public health for decision-making. In 2017, the ACC/AHA classified on the basis of average office BP into four categories -normal, elevated BP, and hypertension Stage 1 and Stage 2. The BP readings used for classification should be an average of two or more readings on two or more different occasions instead of relying on a single value. This classification differs from that previously recommended in the JNC 7 report [4] [ The rationale for the new classification of BP is provided by meta-analysis studies showing hazard ratios for coronary heart disease and stroke were between 1.1 and 1.5 for the comparison of the SBP/DBP of 120-129/80-84 mmHg versus <120/80 mmHg and between 1.5 and 2.0 for the comparison of the SBP/DBP of 130-139/85-89 mmHg versus <120/80 mmHg. This risk gradient was consistent across subgroups defined by sex and race/ethnicity. The relative increase in CVD risk associated with higher BP was attenuated but still present among older adults. [7] The new classification of BP results in a substantial increase in the prevalence of hypertension, but a small increase in the percentage of adults needing antihypertensive medication. The rationale behind this is only the patients with BP of 130-139/80-89 mmHg with atherosclerotic CVD (ASCVD) risk of >10% would be offered treatment, and the remainder should be given advice on lifestyle modification.
Out-Of-Office BP Measurement
The newer guidelines emphasize on the use of either form of out-of-office BP measurement -home BP monitoring (HBPM) or ambulatory BP monitoring (ABPM) for both diagnosis and management of hypertension. Although ABPM is accepted as a better form of out-of-office measurement, HBPM is a more practical form of measurement. Both the methods help in diagnosing and managing "white coat hypertension" and "masked hypertension." The corresponding SBP/DBP values for clinic, HBPM, daytime, nighttime, and 24-h ABPM measurements are shown in Figure 1 .
Evaluation of Hypertension
The newer guidelines emphasize on the evaluation of hypertensive individuals for the risk factors and the evidence for the end-organ damage. The risk factors to be considered are smoking, diabetes, dyslipidemia, sedentary lifestyle, abnormal diet, alcohol intake, obesity, sleep apnea, and stress. Although secondary hypertension accounts for around 10% of hypertensive individuals, multiple clinical scenarios given in Table 2 should alert the physician to search for them. Screening includes testing for common causes such as renal diseases, renovascular disease, primary aldosteronism, obstructive sleep apnea, and drug-and alcohol-induced hypertension. Testing for less common causes such as pheochromocytoma, Cushing's syndrome, congenital adrenal hyperplasia, hypothyroidism, hyperthyroidism, and aortic coarctation to be considered based on clinical indications.
When to Initiate Treatment
The treatment of high BP involves non-pharmacological, pharmacological, and recently device therapies. The nonpharmacological therapy is indicated in all categories of hypertension. The newer guidelines recommend the use of estimating 10-year ASCVD risk of >10% for decision-making in initiation of pharmacotherapy. The limitation of ACC/ AHA CVD risk assessment equation is that it is not applicable for very elderly (>79 years) and it overestimates risk in Asians. The Joint British Society 3 risk score or the World Health Organization-International Society of Hypertension modified risk scores for Southeast Asian region are suited better for Indian population and may be used instead for our patients. [8] The use of pharmacological therapy is recommended for:
• Stage 1 hypertension (SBP ≥130 mmHg or DBP ≥80 mmHg) and an estimated 10-year ASCVD risk of 10% or higher 
Make 130 the New 140 Target Goal
Meta-analyses and systematic reviews of multiple trials comparing an aggressive versus standard BP goals have shown a consistent reduction in stroke, coronary events, and major adverse cardiovascular events. [9] The SPRINT trial showed significant reduction in composite cardiovascular deaths and mortality in the more intense BP control group compared to standard BP group. [10] The guidelines recommend a BP goal of 130/80 mmHg in persons who are on treatment for hypertension. Treatment of hypertension with an SBP treatment goal of 130-139 mmHg is recommended for non-institutionalized ambulatory communitydwelling older adults (>65 years of age) if they tolerate well. For older adults (≥65 years of age) with hypertension and a high burden of comorbidity and limited life expectancy, the clinical judgment, patient preference, and a team-based approach to assess risk/benefit are reasonable for decisions regarding intensity of BP lowering and choice of antihypertensive drugs.
Non-Pharmacological Therapy
The non-pharmacological therapies have very important role in controlling BP and recommended in all stages of hypertension. These interventions help in 2-10 mmHg reduction of BP. The maximum benefit of BP reduction of 11 mmHg is seen with Dietary Approaches to Stop Hypertension (DASH) diet which includes diet rich in fruits, vegetables, whole grains, and low-fat dairy products with reduced content of saturated and total fat. The other interventions include tobacco cessation, weight reduction, low sodium intake of <1.5 g/day, increased potassium intake of 3.5-5 g/day, physical activity, and moderation of alcohol intake.
Pharmacological Therapies
The pharmacological therapies in addition to lifestyle modifications form the primary basis for achieving the target BP goal. Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), calcium channel blockers (CCB), and diuretics are recommended as the first-line antihypertensive agents as they reduce CVD and strokes. Betablockers and alpha-blockers may not be the first-choice drugs as they were the only drug classes that were not significantly superior to any other drug, for any outcomes. [11] The choice of agents depends on the comorbid factors in an individual. In adults with chronic kidney disease, ACE inhibitors/ARBs are preferred. In diabetes mellitus with hypertension, ACE inhibitors or ARBs are considered in the presence of albuminuria. Beta-blockers and/or CCBs might be considered to control hypertension in patients with coronary artery disease. The addition of spironolactone for the treatment of resistant hypertension is considered, unless contraindicated.
The combination of two renin-angiotensin system (RAS) blockers is not recommended due to increased risk of hyperkalemia, cardiovascular events, and reduction in renal function. [12] Similarly, the beta-blockers and thiazide diuretic combinations are not recommended due to metabolic adverse effects.
Reemergence of Chlorthalidone
Thiazide and thiazide-like diuretics have been the mainstay of therapy for primary hypertension since 1960. The BP reduction with diuretics occurs due to initial reduction in plasma volume and cardiac output. The fall in BP later is blunted by hypovolemia-induced RAS activation. Long-term maintenance of the decrease in BP is associated with partial reversal of the initial hemodynamic changes: The plasma volume and cardiac output partially rise toward the baseline level, while the systemic vascular resistance falls.
The initial use of high dose of thiazides to reduce BP resulted in metabolic complications such as hypokalemia, hyponatremia, dyslipidemia, and hyperuricemia, leading to increased incidence of sudden cardiac deaths. [13] Later, the thiazides and thiazide-like diuretics are typically used at low doses of 12.5-25 mg/day of chlorthalidone and hydrochlorothiazide or 1.25 mg/day of indapamide to minimize metabolic complications while maintaining the antihypertensive response. The low-dose chlorthalidone and indapamide are long acting and have shown significant reduction in BP as compared to hydrochlorothiazides with lesser metabolic disturbances. The reductions in cardiovascular events have been noted with chlorthalidone in ALLHAT trial. [14] Due to the longer duration of action with significant reduction in BP and cardiovascular events with lesser metabolic disturbances, the chlorthalidone has emerged as low-dose diuretic of choice in the treatment of hypertension.
Strategies to Improve Hypertension Treatment and Control
Various strategies are planned to achieve sustained BP control below the target BP to reduce CVD and strokes. Initiation with a single antihypertensive drug is reasonable in adults with Stage 1 hypertension (130-139) and in frail very elderly persons in whom sequential addition of other agents is done to achieve the BP target. Initiation of antihypertensive drug therapy with two first-line agents of different classes, either as separate agents or in a single pill combination (SPC), is recommended in adults with hypertension >140/90 mmHg and an average BP >20/10 mmHg above their BP target. The use of SPCs leads to reduction in pill burden, improve compliance, and better control of BP. [15] The preferred combinations are ACEI or ARBs with CCB or diuretics as shown in Figure 2 .
[6] HBPM, ABPM, teambased care, and telehealth strategies all should be used based on availability for better monitoring of BP control and patient compliance.
Device-Based Hypertension Treatment
Various device-based therapies for the treatment of resistant hypertension are under trial to understand the efficacy and safety. Carotid baroreceptor stimulation (pacemaker and stent), renal denervation, and creation of central iliac arteriovenous fistula are tried but are not recommended as there efficacy and safety need to be proved.
Conclusions
Hypertension is the major non-communicable risk factor for increased cardiovascular events. It needs to be detected early and treated adequately to reduce the cardiovascular morbidity and mortality. In this regard, the newer guidelines emphasize on accurate measurement of BP with liberal use of out-of-office BP monitoring methods. The target BP has been reduced to 130/80 mmHg in all hypertension individuals including in those with age >65 years if they tolerate well. The incorporation of CV risk assessment helps in better decision making in the treatment of hypertension. Lifestyle modification is emphasized in all stages of hypertension. The ACE inhibitors, ARBS, CCB, and diuretics are considered as the first-line antihypertensives with chlorthalidone as the diuretic of choice. The use of SPCs is promoted for better control of BP and to improve the compliance. Overall, the newer guidelines emphasized on accuracy of BP measurement, lower BP targets, incorporation of cardiovascular risk assessment in deciding treatment, and strategies to improve BP control which help the clinicians for better management of hypertension.
